RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.

Miller, Robert E

RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. [electronic resource] - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Mar 2014 - 345-54 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1556-1380

10.1097/JTO.0000000000000070 doi


Animals
Anticoagulants--pharmacology
Bone Neoplasms--metabolism
Carcinoma, Non-Small-Cell Lung--metabolism
Enoxaparin--pharmacology
Female
Humans
Lung Neoplasms--metabolism
Mice
Mice, Nude
Osteolysis--drug therapy
Osteoprotegerin--immunology
RANK Ligand--antagonists & inhibitors
Survival Rate
Tumor Burden
Tumor Cells, Cultured